event,time
57 years old ,0
    male ,0
    lepromatous leprosy ,-1440
    skin biopsy ,-1440
    rifampicin ,-1440
    clofazimine ,-1440
    dapsone ,-1440
    abdominal distension ,-1440
    constipation ,-1440
    vomiting ,-1440
    10-kg weight loss ,-1440
    admitted to the hospital ,0
    vital stability ,0
    peripheral lymphadenopathy ,0
    distended abdomen ,0
    positive shifting dullness ,0
    computed tomography scan abdomen ,0
    mural thickening of terminal ileum ,0
    enlarged mesenteric lymph nodes ,0
    mesenteric fat stranding ,0
    intra-abdominal free fluid ,0
    abdominal granulomatous infection ,0
    neoplastic process ,0
    abdominal paracentesis ,0
    atypically large lymphocytes ,0
    high-grade lymphoma ,0
    flow cytometry ,0
    abnormal CD4/CD8 double-negative T-cell population (38%) ,0
    multiple phenotypic aberrancies ,0
    cervical lymph node biopsy ,0
    high-grade peripheral T-cell lymphoma (PTCL) ,0
    NHL subtype ,0
    bone marrow examination ,0
    no involvement of T-cell NHL ,0
    stage IV lymphoma ,0
    dexamethasone ,0
    tumor-lysis syndrome precautions ,0
    clinical deterioration ,0
    transfer to medical ICU ,0
    severe sepsis ,0
    antibiotics ,0
    antifungals ,0
    ICU care for 1 week ,168
    transfer to national cancer center ,168
    EPOCH chemotherapy protocol ,168
    etoposide ,168
    prednisone ,168
    vincristine sulfate (oncovin) ,168
    cyclophosphamide ,168
    doxorubicin hydrochloride (hydroxydaunorubicin) ,168
    six cycles ,168
    CNS prophylaxis (intrathecal methotrexate) ,168
    assessment after four cycles ,672
    complete metabolic remission ,672
    positron emission tomography/computed tomography ,672
    multiple febrile neutropenia episodes ,672
    recurrent bacteremia ,672
    generalized weakness ,672
    no sensory changes ,672
    no clear fatigability ,672
    decreased power in proximal and distal muscles (3/5) ,672
    no other abnormalities ,672
    previous history of ICU admission ,672
    neurotoxic drug use ,672
    malignancy ,672
    differential diagnosis ,672
    critical illness myopathy-neuropathy ,672
    toxic neuropathy ,672
    paraneoplastic syndrome ,672
    neurophysiological electromyogram/nerve conduction study ,672
    normal distal latencies ,672
    normal compound muscle action potential ,672
    normal conduction velocities ,672
    normal F waves ,672
    sensory nerve studies ,672
    normal onset latencies ,672
    normal sensory nerve action potential amplitude ,672
    normal conduction velocities ,672
    needle electromyogram ,672
    proximal muscles ,672
    distal muscles ,672
    lower limbs ,672
    upper limbs ,672
    normal insertional activity ,672
    no spontaneous activity ,672
    normal motor unit action potential ,672
    poor recruitment effects ,672
    repetitive nerve stimulation (30â€“40 Hz) ,672
    significant incremental response ,672
    presynaptic neuromuscular junction disorder ,672
    likely LEMS ,672
    VGCC antibodies requested ,672
    technical issues preventing VGCC antibodies test ,672
    intravenous immunoglobulins for 5 days ,672
    significant improvement of motor function ,672
    ambulate afterward ,672
    dramatic response to treatment ,672
    planned autologous bone marrow transplant ,672
    recurrent bacteremia ,672
    sepsis ,672
    immunocompromised state ,672
    re-admission to medical ICU ,672
    severe sepsis ,672
    multiorgan failure ,672
    passed away ,4320
    remission status maintained ,4320
